PROK: Rilparencel's Q2 2027 readout will test a reparative approach to residual CKD risk

What happened

ProKidney's Phase III trial for rilparencel has enrolled more than 500 patients, with an interim readout on eGFR slope, which tracks how quickly kidney function changes over time, expected in the second quarter of 2027.

Confirmed

Global impact / market context

The readout will test whether rilparencel can repair kidney damage in high-risk chronic kidney disease patients already on standard therapy. Success could support a new treatment approach, while failure would remove a key potential revenue driver for the company.

Analyst inference

Investors are weighing hopeful early findings against the need for clinical proof and lasting benefit. A binary trial result in 2027 means positioning may stay cautious until clearer data on kidney function and durability emerge.

Analyst inference

What to watch

1. Enrollment has passed 500 patients, and the interim eGFR-slope readout is on track for the second quarter of 2027. Confirmed
2. Watch whether ProKidney discloses a specific eGFR-slope target or statistical plan, which would clarify how the interim result will be judged. Proposed
3. Track later data on how long any kidney benefit lasts, because durability questions could limit how doctors use the therapy even if the readout is positive. Analyst inference

Evidence

• Original source link unavailable